In this report, we sought proof that the use of APP translation blockers can reduce amyloid expression pertinent to providing therapy for individuals afflicted with Alzheimer's disease (AD) and Down syndrome (DS). This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.